0
This week on The Downsized News, Christopher and Laraine Durham break down the latest developments shaping the GLP-1 landscape and what they could mean for patients treating the disease of obesity.
New early data reveals that 36% of people starting the new Wegovy pill had never used a GLP-1 before, suggesting oral options may be expanding access rather than simply replacing injections.
They also examine why Eli Lilly is building $1.5 billion in inventory ahead of its anticipated oral GLP-1 launch, and what that could signal about the company's plans to avoid the shortages seen during the rollout of Mounjaro and Zepbound.
Meanwhile, the FDA has issued a warning to Novo Nordisk over a television advertisement for oral Wegovy, calling parts of the messaging false or misleading.
In other stories, AstraZeneca moves its oral GLP-1 candidate into Phase 3, fast food companies including McDonald's begin adapting menus for GLP-1 users, and a new lawsuit raises questions about the marketing of oral tirzepatide.
The episode also explores a growing media narrative around nutrient intake and reduced appetite, and reviews new research from the Clayman Thyroid Center pushing back on fears that GLP-1 medications increase the risk of common thyroid cancers.
Christopher and Laraine share the news, context, and patient relevance to help viewers stay informed as obesity treatment continues to evolve.
New early data reveals that 36% of people starting the new Wegovy pill had never used a GLP-1 before, suggesting oral options may be expanding access rather than simply replacing injections.
They also examine why Eli Lilly is building $1.5 billion in inventory ahead of its anticipated oral GLP-1 launch, and what that could signal about the company's plans to avoid the shortages seen during the rollout of Mounjaro and Zepbound.
Meanwhile, the FDA has issued a warning to Novo Nordisk over a television advertisement for oral Wegovy, calling parts of the messaging false or misleading.
In other stories, AstraZeneca moves its oral GLP-1 candidate into Phase 3, fast food companies including McDonald's begin adapting menus for GLP-1 users, and a new lawsuit raises questions about the marketing of oral tirzepatide.
The episode also explores a growing media narrative around nutrient intake and reduced appetite, and reviews new research from the Clayman Thyroid Center pushing back on fears that GLP-1 medications increase the risk of common thyroid cancers.
Christopher and Laraine share the news, context, and patient relevance to help viewers stay informed as obesity treatment continues to evolve.
